Rescheduling Cannabis-Medicine or Politics?

Area of Science:

• Drug policy analysis
• Pharmacology
• Public health

Background:

• In 2023, the US Department of Health and Human Services (HHS) recommended rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).
• This recommendation represented a significant shift from long-standing federal policy regarding cannabis scheduling.
• The Controlled Substances Act (CSA) outlines specific criteria for drug scheduling, including accepted medical use and abuse potential.

Purpose of the Study:

• To critically evaluate the arguments presented by HHS for recommending the rescheduling of marijuana.
• To assess the validity of HHS's rationale against established legal and scientific criteria for drug scheduling.

Main Methods:

• Analysis of the HHS recommendation letter and supporting documents.
• Critique of the HHS's application of the 8-factor test and 5-part test under the CSA.
• Examination of scientific literature regarding cannabis's medical use, abuse potential, and adverse effects.

Main Results:

• HHS's recommendation introduced new, untested criteria, deviating from established legal standards for rescheduling controlled substances.
• The recommendation inadequately addressed significant adverse effects of cannabis use, including cannabis use disorder, risks to youth, and links to psychosis.
• HHS overstated cannabis's acceptance in medical practice, as few physicians recommend it, and the Food and Drug Administration (FDA) has not approved it due to insufficient evidence.

Conclusions:

• The HHS rationale for rescheduling cannabis is based on a flawed selection of comparator drugs and downplays adverse events.
• The claim of widespread medical acceptance for cannabis is not supported by robust scientific evidence or clinical practice norms.
• The analysis highlights deficiencies in the HHS recommendation, particularly concerning established legal criteria and scientific evidence for cannabis rescheduling.